NCT04676347 Health-care Quality in Semi-intensive Care Units
| NCT ID | NCT04676347 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Condition | Semi-intensive Care Unit |
| Study Type | OBSERVATIONAL |
| Enrollment | 39,000 participants |
| Start Date | 2021-07-01 |
| Primary Completion | 2022-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 39,000 participants in total. It began in 2021-07-01 with a primary completion date of 2022-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of this study is to realize a system of continuous evaluation of healthcare quality in semi-intensive care units.
Eligibility Criteria
Inclusion Criteria: * all patients hospitalised in a semi-intensive care unit Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04676347 clinical trial?
This trial is open to participants of all sexes, studying Semi-intensive Care Unit. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04676347 currently recruiting?
Yes, NCT04676347 is actively recruiting participants. Contact the research team at guido.bertolini@marionegri.it for enrollment information.
Where is the NCT04676347 trial being conducted?
This trial is being conducted at Milan, Italy, Alessandria, Italy, Bassano del Grappa, Italy, Bologna, Italy and 11 additional locations.
Who is sponsoring the NCT04676347 clinical trial?
NCT04676347 is sponsored by Mario Negri Institute for Pharmacological Research. The trial plans to enroll 39,000 participants.